Ultrasound-targeted HSVtk and Timp3 gene delivery for synergistically enhanced antitumor effects in hepatoma

Cancer Gene Therapy

Volumn 20, Issue 5, 2013, Pages 290-297

  Yu, B F ^a   Wu, J ^b,c   Zhang, Y ^b,c   Sung, H W ^d   Xie, J ^a   Li, R K ^b,c  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Antitumor effects; Hepatocellular carcinoma; Herpes simplex virus thymidine kinase; Suicide gene; TIMP3; Ultrasoundtargeted microbubble destruction

Indexed keywords

GANCICLOVIR; SITIMAGENE CERADENOVEC; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE TARGETING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULTRASOUND TARGETED MICROBUBBLE DESTRUCTION;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GANCICLOVIR; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; RANDOM ALLOCATION; SIMPLEXVIRUS; THYMIDINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; MUS; SIMPLEXVIRUS;

EID: 84878016868     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.19     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-236.
3. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12: 1323-1334. (Pubitemid 24173950)
4. Venook AP. Hepatocellular carcinoma. Curr Treat Options Oncol 2000; 1: 407-415.
5. Fuss M, Salter BJ, Cavanaugh SX, Fuss C, Sadeghi A, Fuller CD et al. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int J Radiat Oncol Biol Phys 2004; 59: 1245-1256. (Pubitemid 38834321)
6. Ganne-Carrie N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004; 16: 275-281. (Pubitemid 38368370)
7. Ren W, Strube R, Zhang X, Chen SY, Huang XF. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res 2004; 64: 6645-6651. (Pubitemid 39297925)
8. Gerolami R, Uch R, Faivre J, Garcia S, Hardwigsen J, Cardoso J et al. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol 2004; 40: 291-297. (Pubitemid 38115835)
9. Krohne TU, Shankara S, Geissler M, Roberts BL, Wands JR, Blum HE et al. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 2001; 34: 511-518. (Pubitemid 32786641)
10. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608-614.
11. Heyman RA, Borrelli E, Lesley J, Anderson D, Richman DD, Baird SM et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci USA 1989; 86: 2698-2702. (Pubitemid 19112610)
12. Chen XP, Zhao H, Zhao XP. Alternation of AFP-mRNA level detected in blood circulation during liver resection for HCC and its significance. World J Gastroenterol 2002; 8: 818-821.
13. Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 1999; Suppl: S32-S36. (Pubitemid 29281863)
14. Ala-aho R, Kahari VM. Collagenases in cancer. Biochimie 2005; 87: 273-286. (Pubitemid 40387606)
15. Ahonen M, Ala-aho R, Baker AH, George SJ, Grenman R, Saarialho-Kere U et al. Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 2002; 5: 705-715. (Pubitemid 34619063)
16. Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE et al. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003; 22: 2121-2134. (Pubitemid 36539562)
17. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999; 79: 1347-1355. (Pubitemid 29116789)
18. Finan KM, Hodge G, Reynolds AM, Hodge S, Holmes MD, Baker AH et al. In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer 2006; 53: 273-284. (Pubitemid 44189570)
19. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798-802. (Pubitemid 29086729)
20. Gu P, Xing X, Tanzer M, Rocken C, Weichert W, Ivanauskas A et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 2008; 10: 563-572. (Pubitemid 351770300)
21. Fujii H, Sun Z, Li SH, Wu J, Fazel S, Weisel RD et al. Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice. JACC Cardiovasc Imaging 2009; 2: 869-879.
22. Fujii H, Li SH, Wu J, Miyagi Y, Yau TM, Rakowski H et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J 2011; 32: 2075-2084.
23. Zhou S, Li S, Liu Z, Tang Y, Wang Z, Gong J et al. Ultrasound-targeted microbubble destruction mediated herpes simplex virus-thymidine kinase gene treats hepatoma in mice. J Exp Clin Cancer Res 2010; 29: 170.
24. Tian H, Huang ML, Liu KY, Jia ZB, Sun L, Jiang SL et al. Inhibiting matrix metalloproteinase by cell-based TIMP-3 gene transfer effectively treats acute and chronic ischemic cardiomyopathy. Cell Transplant 2012; 21: 1039-1053.
25. Smith DA, Porter TM, Martinez J, Huang S, MacDonald RC, McPherson DD et al. Destruction thresholds of echogenic liposomes with clinical diagnostic ultrasound. Ultrasound Med Biol 2007; 33: 797-809. (Pubitemid 46654545)
26. Anderson WF. Human gene therapy. Nature 1998; 392: 25-30. (Pubitemid 28215190)
27. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245. (Pubitemid 30016842)
28. Lentacker I, De Geest BG, Vandenbroucke RE, Peeters L, Demeester J, De Smedt SC et al. Ultrasound-responsive polymer-coated microbubbles that bind and protect DNA 55. Langmuir 2006; 22: 7273-7278. (Pubitemid 44366426)
29. Panje C, Wang DS, Pysz MA, Paulmurugan R, Ren Y, Tranquart F et al. Ultrasoundmediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency. Theranostics 2012; 2: 1078-1091.
30. Sun L, Huang CW, Wu J, Chen KJ, Li SH, Weisel RD et al. The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium 67. Biomaterials 2013; 34: 2107-2116.
31. Carson AR, McTiernan CF, Lavery L, Hodnick A, Grata M, Leng X et al. Gene therapy of carcinoma using ultrasound-targeted microbubble destruction. Ultrasound Med Biol 2011; 37: 393-402.
32. Tang Q, He X, Liao H, He L, Wang Y, Zhou D et al. Ultrasound microbubble contrast agent-mediated suicide gene transfection in the treatment of hepatic cancer. Oncol Lett 2012; 4: 970-972.
33. Hanke P, Serwe M, Dombrowski F, Sauerbruch T, Caselmann WH. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther 2002; 9: 346-355. (Pubitemid 34289453)
34. Horst M, Brouwer E, Verwijnen S, Rodijk M, de JM, Hoeben R et al. Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med 2007; 9: 1071-1079. (Pubitemid 350286412)
35. McKie EA, Graham DI, Brown SM. Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector-potential glioblastoma targeting. Gene Ther 1998; 5: 440-450. (Pubitemid 28200635)
36. Vollmer Jr. CM, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59: 3064-3067. (Pubitemid 29316002)
37. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3: 85-92. (Pubitemid 26088496)
38. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1996; 271: 2874. (Pubitemid 26047911)
39. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases- 3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994; 269: 9352-9360. (Pubitemid 24209266)
40. Yu WH, Yu S, Meng Q, Brew K, Woessner Jr. JF. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275: 31226-31232.